Exercise to Prevent Depression and Anxiety in Older Hispanics
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Anxiety
- Sponsor
- University of Miami
- Enrollment
- 60
- Locations
- 1
- Primary Endpoint
- Prevention of major depression, generalized anxiety, and social anxiety as measured the Mini International Neuropsychiatric Interview
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
The study is a randomized pilot trial of a health promotion intervention in the prevention of anxiety and depression in older Hispanics.
Detailed Description
Eligible participants will be randomized to either the Happy Older Latinos are Active (HOLA) intervention or a psychoeducation condition. Participants randomized to HOLA will participate in a group exercise, 3 times a week, for 16 weeks. The exercise is a moderate intensity walk at a centrally located park in Miami-Dade county and will last for an hour (10 minute warmup/stretching, 30 minute walk, 5 minute cool down). Groups will consist of 6 participants and be led by a community health worker. During the cool down phase, participants will plan a pleasant event to be done in between sessions. Participants randomized to the psychoeducation component will receive a fotonovela and will meet once a month after they receive the fotonovela to discuss their thoughts on the materials they received. These discussion groups will last one hour and will consist of 10 participants. A total of 60 participants will be randomized (30 to HOLA, 30 to fotonovela). Assessments will be conducted at baseline, post intervention, 6 months post-intervention, and 12 months post-intervention.
Investigators
Daniel Enrique Jimenez
Assistant Professor
University of Miami
Eligibility Criteria
Inclusion Criteria
- •Hispanic (self-identified);
- •Minor depression as defined by a primary DSM-IV Axis I diagnosis of minor depressive disorder or subthreshold depression defined as a score ≥ 3 on the Patient Health Questionnaire (PHQ-2), OR subthreshold anxiety as defined as a score ≥ 3 on the Generalized Anxiety Disorder-2 scale (GAD-2);
- •Absence of episodes of major depression and anxiety disorders for past 12 months (as determined by the MINI);
- •Voluntary informed consent for participation in the study by the participant or by the participant's legally designated guardian or conservator;
- •Medical clearance for participation in an exercise program by a physician, physician's assistant, or nurse practitioner;
- •Expect to be resident in Miami for the subsequent 12 months.
Exclusion Criteria
- •Currently residing in a nursing or group home;
- •A terminal physical illness expected to result in the death within one year;
- •A diagnosis of dementia, co-morbid diagnosis of dementia, or significant cognitive impairment as indicated by an MMSE score \<24;
- •Presence of any axis 1 psychiatric disorder or substance abuse during preceding 12 months;
- •History of psychiatric disorders other than non-psychotic unipolar major depression or anxiety disorder;
- •High suicide risk, i.e., intent or plan to attempt suicide in the near future (a response of "yes" to questions 3, 4, and/or 5 on the Paykel Questionnaire);
- •Participants taking cognitive enhancing medication or psychotropic medications (e.g. antidepressants);
- •unable to complete 400 m walk test in less than 15 min;
- •if participant heart rate exceeded 170 beats per minute OR systolic blood pressure exceeds 180 during 400 m walk test;
- •chest or leg pain, dyspnea, dizziness, feeling faint, or other significant symptoms while completing 400 m walk test;
Outcomes
Primary Outcomes
Prevention of major depression, generalized anxiety, and social anxiety as measured the Mini International Neuropsychiatric Interview
Time Frame: change from baseline at 16 months
I will be using the Mini International Neuropsychiatric Interview to test whether the HOLA intervention was successful in preventing participants from getting major depressive disorder, generalized anxiety disorder, and social anxiety disorder.
Secondary Outcomes
- Self-efficacy as measured by the General Self-Efficacy Scale(change from baseline at 16 months)
- Physical functioning as measured by the World Health Organization Disability Assessment Schedule 2.0 (WHO-DAS 2)(change from baseline at 16 months)
- Change in depression symptom severity as measured by the Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR).(change from baseline at 16 months)
- Social functioningas measured by the World Health Organization Disability Assessment Schedule 2.0 (WHO-DAS 2)(change from baseline at 16 months)
- Sleep quality as measured by the Pittsburgh Sleep Quality Index(change from baseline at 16 months)
- Change in anxiety symptom severity as measured by the Beck Anxiety Inventory (BAI)(change from baseline at 16 months)